Interneuron regulatory update

The Drug Enforcement Agency (DEA) recommended that fenfluramine and its isomers, including dexfenfluramine, be removed from Schedule IV and all other controls of the Controlled Substances Act. Dexfenfluramine is the active ingredient in IPIC's Redux obesity drug. As a Schedule IV substance, Redux is subject to controls related to record-keeping for dispensing pharmacists and procedural mandates for prescribing physicians. ...